New hope for rare disease: can NS-229 help patients reduce steroids?

NCT ID NCT06046222

Ongoing Disease control Sponsor: NS Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid dose. Participants will receive either NS-229 or a placebo, and doctors will check disease activity and steroid use after 28 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHURG-STRAUSS SYNDROME EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Contacts and locations

Show contact details

Locations

Addenbrookes Hospital

Cambridge, CB2 2QQ, United Kingdom
Azienda Ospedaliera Universitaria Integrata Verona

Verona, 37126, Italy
Azienda Provinciale per i Servizi Sanitari Provincia Autonoma Trento

Trento, 38122, Italy
CHU Nice

Nice, 06202, France
Chiba University Hospital

Chuo-ku, Chiba-shi, Chiba, 260-8677, Japan
Chu Rangueil

Toulouse, 31059, France
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Complejo Hospitalario Universitario de Santiago de Compostela

Santiago de Compostela, A Coruna, 15706, Spain
Complejo Hospitalario de Navarra

Pamplona, 31008, Spain
Fondazione Policlinico Universitario Campus Bio-Medico

Roma, 00128, Italy
Hokkaido University Hospital

Sapporo, Hokkaido, 060-8648, Japan
Hopital Cochin

Paris, 75014, France
Hospital of the University of Occupational and Environmental Health, Japan

Kitakyushu, Fukuoka, 807-8555, Japan
Istituto Auxologico Italiano IRCCS

Milan, 20145, Italy
Juntendo University Hospital

Bunkyo-ku, Tokyo, 113-8431, Japan
Kyorin University Hospital

Mitaka, Tokyo, 181-8611, Japan
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Medius Kliniken gGmbh

Kirchheim unter Teck, Studienzentrale, 73230, Germany
NHO Sagamihara National Hospital

Sagamihara, Kanagawa, 252-0392, Japan
National Hospital Organization Yokohama Medical Center

Yokohama, Kanagawa, 245-8575, Japan
National Jewish Health

Denver, Colorado, 80206, United States
Osaka Habikino Medical Center

Habikino, Osaka, 583-8588, Japan
Queen Elizabeth Hospital Birmingham

Edgbaston, Birmingham, B15 2GW, United Kingdom
Royal Berkshire NHS Foundation Trust

Reading, RG1 5AN, United Kingdom
Saitama Medical Center

Kawagoe, Saitama, 350-8550, Japan
St Joseph's Healthcare Hamilton

Hamilton, Ontario, L8N4A6, Canada
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
Toho University Omori Medical Center

Ōta-ku, Tokyo, 143-8541, Japan
Tohoku University Hospital

Sendai, Miyagi, 980-8574, Japan
University of Alberta

Edmonton, Alberta, T6G 2B7, Canada
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Toronto

Toronto, Ontario, M5G 1X5, Canada
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States